Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
By C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J. Travagli, B. Caillou, M. Ricard, J. Lumbroso, F. Vathaire and 1 more. Journal of Clinical Endocrinology and Metabolism, 2006
1,569 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/76966c919f3520170c07ed45ec60e9bf9f948e0c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Guidelines for radioiodine therapy of differentiated thyroid cancer (2008, background): “local recurrences, lymph node metastases or disseminated iodineavid lung metastases or other distant lesions, has shown in various investigations to be effective in eradicating disease, slowing disease progression or providing symptomatic relief [ 4 ].”
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System (2010, methodology): “This is based on previous studies demonstrating that risk of persistent disease or recurrence is altered by the completeness of initial surgery, changes in serum thyroglobulin (Tg) or anti-Tg antibody levels (TgAb) over time (13–18), the degree of RAI avidity of pulmonary metastases (19), the presen”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “One-third of patients have lesions that are not RAI-avid and are considered RAI-refractory [IV, A] (Figure 2) [73, 76].”
- Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, neutral): “Lung macronodules may benefit from radioiodine therapy but the definitive cure rate is very low [28] (IV, B).”
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “If RAI is being considered, stereotactic EBRT and concomitant glucocorticoid therapy are recommended prior to RAI therapy to minimize the effects of a potential TSH-induced increase in tumor size and RAI-induced inflammatory response.”
- [Papillary and follicular thyroid carcinoma]. (2007, background): “[6] Durante C, Haddy N, Baudin E, et al.”